Srs Capital Advisors, Inc. Cassava Sciences Inc Transaction History
Srs Capital Advisors, Inc.
- $1.48 Billion
- Q1 2025
A detailed history of Srs Capital Advisors, Inc. transactions in Cassava Sciences Inc stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 445 shares of SAVA stock, worth $996. This represents 0.0% of its overall portfolio holdings.
Number of Shares
445Holding current value
$996% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SAVA
# of Institutions
155Shares Held
15.6MCall Options Held
1.67MPut Options Held
1.26M-
Black Rock Inc. New York, NY3.22MShares$7.21 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.44MShares$5.47 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.03MShares$2.3 Million0.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny909KShares$2.04 Million0.0% of portfolio
-
State Street Corp Boston, MA874KShares$1.96 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $89.8M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...